TAVI Today: Current Evidence Across All Risk Groups
TAVI Today: Current Evidence Across All Risk Groups
Following the recently published 10-year PARTNER 2 results, the current evidence can be summarized as follows:
• High-Risk/Inoperable Patients: TAVI is an established alternative to surgery.
• Intermediate-Risk Symptomatic AS (PARTNER 2): Modern TAVI matches SAVR at 10 years.
• Low-Risk Symptomatic AS (PARTNER 3 & Evolut Low Risk): Excellent outcomes through 7–8 years; 10-year durability data are awaited.
• Asymptomatic Severe AS (EARLY TAVR): Early TAVR improves 5-year clinical outcomes versus watchful waiting.
Take-Home Message
Modern TAVI has evolved from a treatment for inoperable patients to the preferred therapy for many elderly patients with severe aortic stenosis. Current evidence supports TAVI as a durable lifetime solution for most patients aged ≥80 years. Whether the same benefit extends to younger, low-risk patients will depend on the ongoing 10-year follow-up of the PARTNER 3 and Evolut Low Risk trials.
Choosing Between TAVR and SAVR :
Comprehensive Heart Team Assessment Beyond the STS Score
• STS surgical risk score
• Life expectancy
• Bicuspid vs tricuspid aortic valve
• Coronary anatomy and future coronary access
• Need for concomitant cardiac surgery
• CT anatomical suitability
• Patient preference and Heart Team discussion
Sources: NY Valves 2026/TCTMD (PARTNER 3, Evolut Low Risk, and EARLY TAVR updates), June 24–26, 2026
https://www.tctmd.com/news/new-10-year-tavi-data-generally-reassuring-highlight-challenges
